Home » Stocks » RedHill Biopharma

RedHill Biopharma Ltd. (RDHL)

Stock Price: $8.10 USD -0.27 (-3.23%)
Updated Aug 14, 2020 12:17 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 285.68M
Revenue (ttm) 5.61M
Net Income (ttm) -42.30M
Shares Out 35.27M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $8.10
Previous Close $8.37
Change ($) -0.27
Change (%) -3.23%
Day's Open 8.37
Day's Range 7.93 - 8.40
Day's Volume 239,435
52-Week Range 3.26 - 10.17

More Stats

Market Cap 285.68M
Enterprise Value 241.63M
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 35.27M
Float 20.84M
EPS (basic) -1.4
EPS (diluted) -1.58
FCF / Share -1.44
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.80M
Short Ratio 7.02
Short % of Float n/a
Beta 1.78
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 50.92
PB Ratio 7.25
Revenue 5.61M
Operating Income -43.20M
Net Income -42.30M
Free Cash Flow -40.92M
Net Cash 44.06M
Net Cash / Share 1.25
Gross Margin 71.87%
Operating Margin -770.07%
Profit Margin -672.50%
FCF Margin -729.36%
ROA -31.12%
ROE -115.97%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.50*
(153.09% upside)
Low
16.0
Current: $8.10
High
27.0
Target: 20.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue6.298.364.010.10-7.010.010.020.02-
Revenue Growth-24.75%108.63%3867.33%3266.67%-99.96%58350%-25%-30.43%--
Gross Profit4.035.521.880.10-5.960.010.020.02-
Operating Income-43.20-39.33-51.13-30.54-21.90-10.65-10.77-9.04-7.87-1.25
Net Income-42.30-38.82-45.54-29.37-21.09-10.71-10.63-10.33-15.50-2.54
Shares Outstanding28421317112787.8864.4052.9952.99--
Earnings Per Share-1.40-1.70-2.60-2.40-1.90-1.30-1.70-2.00-3.20-2.70
Operating Cash Flow-40.75-34.46-44.77-28.26-17.83-12.23-8.44-6.80-4.69-1.63
Capital Expenditures-0.17-0.02-0.15-0.09-0.01-0.07-0.01-0.01-0.14-0.01
Free Cash Flow-40.92-34.49-44.92-28.34-17.84-12.30-8.45-6.80-4.83-1.64
Cash & Equivalents47.8753.1946.2166.1558.1422.9512.1118.3718.659.15
Total Debt3.82--------11.25
Net Cash / Debt44.0653.1946.2166.1558.1422.9512.1118.3718.65-2.09
Assets74.1062.4157.3474.2166.8328.8614.3420.1020.1910.51
Liabilities14.1011.2312.2811.516.753.852.421.081.4012.10
Book Value60.0051.1945.0762.7060.0825.0111.9319.0218.79-1.59
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name RedHill Biopharma Ltd.
Country Israel
Employees 155
CEO Dror Ben-Asher

Stock Information

Ticker Symbol RDHL
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: RDHL

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases. The company promotes various gastrointestinal drugs, including Movantik for opioid-induced constipation in adults; Talicia for the treatment of Helicobacter pylori bacterial infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its late-stage clinical development programs include RHB-104, which is in Phase 3 study for treating Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) that is in first Phase 3 study to treat acute gastroenteritis and gastritis, as well as has completed Phase 2 study for treating irritable bowel syndrome with diarrhea; RHB-106, which is in planned Phase 2/3 studies for bowel preparation; ABC294640 (Yeliva), a SK2 selective inhibitor, which is in Phase 1/2a study for treating cholangiocarcinoma, as well as in Phase 2 study for prostate cancer; and RHB-107 that is in planned pilot study for cholangiocarcinoma, as well as has completed Phase 2 study for gastrointestinal and other solid tumors. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.